Effectively Immediately, Vivos to be Exclusive Distributor for Novel Diagnostic Equipment to Evaluate Nasal Breathing and Function in Dental Patients...
SEATTLE and VANCOUVER, British Columbia, June 29, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical...
Rucosopasem was safe and well tolerated Early indications of anti-cancer activity and pulmonary function preservation Enrollment ongoing in the randomized,...
The Lab™ Live Resin’s Full-Spectrum, Aromatic Hydrocarbon Extracts Deliver Precise Effects, Flavorful Terpenes, High Purity and Freshness Jushi Holdings Debuts...
Leverages Mindset’s Platform Technology for Efficient Delivery of CNS TherapeuticsTORONTO, June 29, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE:...
Orphan Drug Designation granted for treatment of pyoderma gangrenosum (PG) from US FDA and EMAProductive end-of-phase II meeting with FDA...
BASEL, Switzerland, June 29, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel...
Neurona has initiated dosing of a first-ever regenerative human cell therapy candidate in a Phase 1/2 clinical trial for epilepsy...
CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target...
LEAMINGTON, Ontario, June 29, 2022 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a...
Overall response rate of 24%, and disease control rate of 73%, in heavily pre-treated patients with a median of 4...
Successfully delivered ketamine and KETABET™ (ketamine and betaine) via microneedle patch, unlocking the potential for desired dosage forms and pharmacokinetic...
Responding to Consumers, Management Offers Cost-Effective Combination With Enhanced Synergistic Benefits LAS VEGAS, NV , June 29, 2022 (GLOBE NEWSWIRE)...
SOUTH SAN FRANCISCO, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage...
AN2 is developing epetraborole as a once-daily, orally administered treatment with a novel mechanism of action for patients with NTM...
MiroBio Raises $97 Million Series B Financing to Develop Checkpoint Agonists for Treatment of Autoimmune Diseases Financing led by Medicxi...
Patients on ALRN-6924 were able to stay on treatment longer, completing more of the first 4 cycles of carboplatin/pemetrexed (93%...
VANCOUVER, British Columbia, June 29, 2022 (GLOBE NEWSWIRE) -- Reliq Health Technologies Inc. (TSXV:RHT) (OTCPink:RQHTF) (FSE:MHN2), a rapidly growing global...
Oculis Announces First Patient Enrolled in Phase 3 OPTIMIZE Trial of OCS-01 in the Treatment of Inflammation and Pain Following...
MiroBio Raises $97 Million Series B Financing to Develop Checkpoint Agonists for Treatment of Autoimmune Diseases Financing led by Medicxi...